GTS Securities’s Bristol-Myers Squibb BMY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q4
Sell
-299,500
Closed -$15.5M 1601
2024
Q3
$15.5M Buy
299,500
+179,400
+149% +$8.42M 0.03% 339
2024
Q2
$4.99M Sell
120,100
-70,600
-37% -$3.16M 0.01% 861
2024
Q1
$10.3M Buy
190,700
+45,900
+32% +$2.34M 0.02% 497
2023
Q4
$7.43M Sell
144,800
-5,800
-4% -$304K 0.01% 765
2023
Q3
$8.74M Buy
+150,600
New +$9.23M 0.02% 655

Other funds holding BMY

GTS Securities's BMY Position: Q2 2026 in Review

GTS Securities sold out of Bristol-Myers Squibb (BMY) in Q2 2026, closing a stake of 6,135 shares — an estimated $372K sold.

GTS Securities first reported a position in BMY in Q2 2023 and held it in 12 quarters. The position peaked at $13.5M in Q4 2023. 2,524 funds tracked by Wall St. Rank hold BMY as of Q2 2026.

  • GTS Securities reported no remaining Bristol-Myers Squibb position as of Q2 2026 after selling out during the quarter.
  • GTS Securities sold 6,135 Bristol-Myers Squibb shares in Q2 2026, an estimated $372K.
  • GTS Securities first reported a position in Bristol-Myers Squibb in Q2 2023 and held it in 12 quarters.
  • GTS Securities's Bristol-Myers Squibb position peaked at $13.5M in Q4 2023.
  • 2,524 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2026.

Based on GTS Securities's 13F filing for Q2 2026, filed 14 Aug 2026.